Report overview
Measuring the activity of cancer cells in the body High levels of CEA in adults can be a marker for certain types of cancer in organs such as the colon and rectum, prostate, ovary, lung, thyroid or liver. These kits allow you to quickly and initially test for cancer.
This report contains market size and forecasts of Cancer Rapid Diagnostic Kit in global, including the following market information:
Global Cancer Rapid Diagnostic Kit Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global Cancer Rapid Diagnostic Kit Market Sales, 2018-2023, 2023-2030, (K Units)
Global top five Cancer Rapid Diagnostic Kit companies in 2022 (%)
The global Cancer Rapid Diagnostic Kit market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Test Gene Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Cancer Rapid Diagnostic Kit include Asuragen, Beijing ACCB Biotech Ltd., Shenzhen Kangshengbao Biotechnology, XIAMEN SPACEGEN CO.,LTD, Genetic Biotek, Jiangsu Mole Bioscience CO., LTD., Kolplast Group, LCM Genect and OptiBio Co., Ltd., etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cancer Rapid Diagnostic Kit manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Rapid Diagnostic Kit Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Cancer Rapid Diagnostic Kit Market Segment Percentages, by Type, 2022 (%)
Test Gene
Test For Tumor Markers
Test Protein
Others
Global Cancer Rapid Diagnostic Kit Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Cancer Rapid Diagnostic Kit Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Global Cancer Rapid Diagnostic Kit Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Cancer Rapid Diagnostic Kit Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Rapid Diagnostic Kit revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Cancer Rapid Diagnostic Kit revenues share in global market, 2022 (%)
Key companies Cancer Rapid Diagnostic Kit sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Cancer Rapid Diagnostic Kit sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Asuragen
Beijing ACCB Biotech Ltd.
Shenzhen Kangshengbao Biotechnology
XIAMEN SPACEGEN CO.,LTD
Genetic Biotek
Jiangsu Mole Bioscience CO., LTD.
Kolplast Group
LCM Genect
OptiBio Co., Ltd.
Panagene Inc.
Sansure Biotech
Seegene
Shanghai Outdo Biotech Co., Ltd.
Xian Tianlong Science and Technology Co.,Ltd
Yaneng Bioscience (Shenzhen) Co., Ltd.
GenomeMe Labs Inc
IDL Biotech
Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
ShenZhen Zijian Biotechnology Co.,Ltd.
ViennaLab Diagnostics
Xiamen Biotime Biotechnology Co., Ltd.
Jiangsu MicroDiag Biomedicine Technology Co., Ltd.
Bioscience (Tianjin) Diagnostic Technology Co.,Ltd
Boditech Med Inc.
Diagenode
Fujirebio
Gencurix
